[Anti-platelet aggregation therapy and ischaemic cerebral accidents due to atheroma (author's transl)].
Most controlled studies of the effects of anticoagulants on ischaemic cerebral accidents due to atheroma were carried out in the 60's and failed to show long-term beneficial results. Anti-platelet aggregation agents, such as dipyridamole, clofibrate and sulfinpyrazone, did not prove more effective. A well-conducted co-operative Canadian study has recently shown that aspirin in doses of 1300 mg/day reduced by 19% the risk of ischaemic cerebral accident or death and that this risk is further reduced in the subgroup of non-diabetic male patients without history of infarction. Another American co-operative study suggests that aspirin is more effective in patients who had several transient episodes of cerebral ischaemia and that an atheromatous lesion is present. No combination of anti-platelet aggregation agents is demonstrably superior to aspirin. The present tendency is to administer heparin immediately after ischaemic cerebral accidents.
D000925:Anticoagulants / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000150:complications*; D001241:Aspirin / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*
D000925:Anticoagulants; D001241:Aspirin
Traitement anti-agrégant plaquettaire de la pathologie ischémique cérébrale liée à l'athérome.